Boston Scientific to Present New Data on Advances in Chronic Pain Care at the 2022 North American Neuromodulation Society (NANS) Meeting

Rhea-AI Summary

Boston Scientific Corporation (NYSE: BSX) will present significant findings at the 25th North American Neuromodulation Society annual meeting in Orlando, Florida, from Jan. 13-15, 2022. Key highlights include a late-breaking presentation on the COMBO study, demonstrating the effectiveness of the WaveWriter™ Spinal Cord Stimulator System over two years. Additionally, updates on collaborations with IBM Research will showcase innovative AI-driven approaches to assess patient pain states.

Over 20 abstracts will be presented, emphasizing Boston Scientific's commitment to personalized chronic pain therapies.

MARLBOROUGH, Mass., Jan. 7, 2022 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced key data that will be featured at the 25^th North American Neuromodulation Society (NANS) annual meeting, in Orlando, Florida, on Jan.13-15, 2022. More than 20 abstracts have been accepted, including three late-breaking presentations.

The late-breaking presentation on the COMBO study, a randomized control trial, will highlight two-year outcomes demonstrating the durable effectiveness of the WaveWriter™ Spinal Cord Stimulator (SCS) System capable of delivering combination therapy – the ability to layer multiple waveforms and modalities simultaneously. Combination therapy is designed to offer more opportunities to customize SCS therapy and optimize outcomes.

In addition, Boston Scientific and IBM Research will provide an update from their exclusive collaboration, which includes the ongoing NAVITAS and ENVISION studies evaluating how patient-reported outcomes and objective biomarker information can provide insights around patient pain states. This novel approach leverages artificial intelligence to better understand and assess the pain state of an individual that includes activity, alertness, medication, mobility, mood, pain and sleep.

"The data we'll share this year at NANS is a testament to the breadth and depth of the randomized, controlled and real-world evidence of our portfolio and therapies," said Nilesh Kumar Patel, M.D., MBA, vice president of medical affairs, Neuromodulation, Boston Scientific. "Our long-term investments in science and innovation continue to deliver more meaningful solutions and customized options for physicians and their patients living with chronic pain."

Patel added, "The condition of chronic pain is complex, and because of neuroplasticity, it changes over time. As a result, you need an agile platform with multiple options that adapts with the changing needs of the patient. No one patient living with chronic pain is the same so we're continuously working to advance and transform personalized therapies for the future to help patients live healthier lives."

Featured Abstracts

Oral Presentations:

• COMBO Randomized Control Trial: Two-Year Outcomes of an SCS System Capable of Simultaneous Delivery of Multiple Modalities to be presented by Mark Wallace, M.D., on Saturday, Jan. 15 from 4:25-4:35 p.m. ET
• Patient States: Artificial Intelligence-Driven Metric Providing Comprehensive Yet Straightforward Understanding of Chronic Pain Patients to be presented by Magdalena Anitescu, M.D., Ph.D., on Friday, Jan. 14 from 11:35-11:45 a.m. ET
• Prospective, Multi-Center Evaluation of Novel Fast-Acting Sub-Perception-Based SCS for Chronic Pain: FAST Study to be presented by Magdalena Anitescu, M.D., Ph.D., on Friday, Jan. 15 from 4:15-4:25 p.m. ET

Paper Posters:

• RAPID: An International, Prospective, Multicenter Study of Radiofrequency Ablation Outcomes in Chronic Pain Patients, Atallah et al.
• Comprehensive Digital Tools to Improve Access to Care and Treatment Efficiency for Spinal Cord Stimulation, Vucetic et al. 
• Modeling and Measurement of the Effect of Low-Amplitude SCS on Dorsal Column Axons and Wide Dynamic Range Neurons, Titus et al.
• The Biomechanics of Interspinous Spacers, Whang et al.

Publication will be made available after the release of the data presentations.

About the Boston Scientific Chronic Pain Portfolio
Where many "one-size fits all" treatments fail to provide long-term relief, Boston Scientific understands that it takes personalized pain relief solutions to improve patient outcomes. The WaveWriter Alpha™ Spinal Cord Stimulator (SCS) Systems include a unified portfolio of four MRI conditionalⁱ, Bluetooth-enabled rechargeable and non-rechargeable implantable pulse generators to provide uncompromised personalization, and for the first time in SCS, Fast Acting Sub-perception Therapy (FAST™), designed to deliver profound paresthesia-free pain relief in minutes. The systems are supported by the Cognita™ Solutions suite of digital tools for patients and physicians. Other solutions include the Vertiflex™ Procedureⁱⁱ, a unique treatment clinically proven to provide long-term relief from pain associated with moderate lumbar spinal stenosis, and the Radiofrequency Ablation (RFA) offerings for physicians help treat chronic pain with a minimally invasive, non-surgical, outpatient procedure that uses thermal energy to interrupt pain signals at their source.

About Boston Scientific
Boston Scientific transforms lives through innovative medical solutions that improve the health of patients around the world. As a global medical technology leader for more than 40 years, we advance science for life by providing a broad range of high-performance solutions that address unmet patient needs and reduce the cost of healthcare. For more information, visit www.bostonscientific.com and connect on Twitter and Facebook.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding our business plans and product performance and impact. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements. 

Factors that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation; financial market conditions; and future business decisions made by us and our competitors. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A – Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A – Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file hereafter. We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements. This cautionary statement is applicable to all forward-looking statements contained in this document.

CONTACTS:

Media:
Jessica Sachariason
+1.415.730.2310
jessica.sachariason@bsci.com 

Investor Relations:
Lauren Tengler
+1.508.683.4479
lauren.tengler@bsci.com

ⁱ _{The WaveWriter Alpha™ SCS System provides safe access to full-body MRI scans when used with specific components and the patient is exposed to the MRI environment under the defined conditions in the ImageReady™ MRI Full Body Guidelines for WaveWriter Alpha and WaveWriter Alpha Prime Spinal Cord Stimulator System}
ⁱⁱ _{Superion™ Indirect Decompression System}

 

View original content:https://www.prnewswire.com/news-releases/boston-scientific-to-present-new-data-on-advances-in-chronic-pain-care-at-the-2022-north-american-neuromodulation-society-nans-meeting-301456068.html

SOURCE Boston Scientific Corporation

FAQ

What new data will Boston Scientific present at the NANS meeting 2022?

Boston Scientific will present findings on the COMBO study, highlighting two-year outcomes of the WaveWriter™ Spinal Cord Stimulator System.

When is the NANS meeting where Boston Scientific will present?

The NANS meeting takes place from January 13-15, 2022, in Orlando, Florida.

What are the key features of the WaveWriter™ SCS System?

The WaveWriter™ SCS System offers combination therapy, allowing multiple waveforms and modalities to be delivered simultaneously for optimized pain relief.

What is the focus of the collaboration between Boston Scientific and IBM Research?

The collaboration aims to evaluate patient-reported outcomes and biomarkers to gain insights into individual pain states using artificial intelligence.

Who will present the findings from the COMBO study?

Mark Wallace, M.D., will present the findings from the COMBO study on January 15, 2022.

How does Boston Scientific's approach to chronic pain differ?

Boston Scientific emphasizes personalized pain relief solutions over 'one-size fits all' treatments to improve patient outcomes.